Symbols / GLMD $0.52 -1.03% Galmed Pharmaceuticals Ltd.

Healthcare • Biotechnology • Israel • NCM
GLMD Chart
About

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 3.43M
Enterprise Value -14.60M Income -10.31M Sales —
Book/sh 3.49 Cash/sh 2.76 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -0.51 PEG —
P/S — P/B 0.15 P/C —
EV/EBITDA 1.73 EV/Sales — Quick Ratio 6.50
Current Ratio 6.55 Debt/Eq — LT Debt/Eq —
EPS (ttm) -2.39 EPS next Y -1.03 EPS Growth —
Revenue Growth — Earnings 2026-03-31 16:00 ROA -28.65%
ROE -64.21% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 6.58M
Shs Float 6.37M Short Float 0.27% Short Ratio 0.35
Short Interest — 52W High 2.68 52W Low 0.41
Beta — Avg Volume 50.16K Volume 33.10K
Target Price — Recom None Prev Close $0.53
Price $0.52 Change -1.03%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.52
Latest analyst target
3. DCF / Fair value
$-11.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.52
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-04 down Maxim Group Buy → Hold —
2023-07-24 up Maxim Group Hold → Buy $4
2022-08-08 down Maxim Group Buy → Hold —
2022-08-08 down Canaccord Genuity Buy → Hold $1
2022-05-18 down Raymond James Outperform → Market Perform —
2022-05-03 down HC Wainwright & Co. Buy → Neutral —
2022-05-03 main Raymond James — → Outperform $5
2021-05-17 main Canaccord Genuity — → Buy $21
2021-03-19 main HC Wainwright & Co. — → Buy $25
2021-01-08 main Raymond James — → Outperform $17
2020-11-25 main Canaccord Genuity — → Buy $20
2020-05-22 down B. Riley Securities Buy → Neutral $8
2020-05-15 main Raymond James — → Outperform $20
2020-03-13 main Stifel — → Buy $25
2020-03-13 main B. Riley Securities — → Buy $11
2020-02-04 init Craig-Hallum — → Buy $18
2019-07-22 init Laidlaw & Co. — → Buy $25
2018-12-12 init B. Riley Securities — → Buy $28
2018-07-20 init Raymond James — → Outperform $26
2018-07-13 init Stifel — → Buy $35
News
RSS: Latest GLMD news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
8.51
+35.55%
6.28
-16.20%
7.49
-57.55%
17.65
Research And Development
4.87
+63.61%
2.98
-16.53%
3.57
-72.54%
12.99
Selling General And Administration
3.64
+10.22%
3.30
-15.91%
3.92
-15.74%
4.66
General And Administrative Expense
3.64
+10.22%
3.30
-15.91%
3.92
-15.74%
4.66
Salaries And Wages
2.33
+22.56%
1.90
-8.67%
2.08
+0.00%
2.08
Other Gand A
0.90
+0.33%
0.90
-1.32%
0.91
-16.24%
1.08
Total Expenses
8.51
+35.55%
6.28
-16.20%
7.49
-57.55%
17.65
Operating Income
-8.51
-35.55%
-6.28
+16.20%
-7.49
+57.55%
-17.65
Total Operating Income As Reported
-8.51
-35.55%
-6.28
+16.20%
-7.49
+57.55%
-17.65
EBITDA
-8.51
-37.37%
-6.20
+16.97%
-7.46
+57.65%
-17.62
Normalized EBITDA
-5.89
-16.03%
-5.08
+33.85%
-7.68
+55.17%
-17.13
Reconciled Depreciation
0.00
-100.00%
0.08
+167.74%
0.03
-11.43%
0.04
EBIT
-8.51
-35.55%
-6.28
+16.20%
-7.49
+57.55%
-17.65
Total Unusual Items
-2.62
-134.38%
-1.12
-617.13%
0.22
+144.08%
-0.49
Total Unusual Items Excluding Goodwill
-2.62
-134.38%
-1.12
-617.13%
0.22
+144.08%
-0.49
Special Income Charges
-2.46
-114.93%
-1.15
0.00
0.00
Write Off
2.46
+114.93%
1.15
0.00
0.00
Net Income
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Pretax Income
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Net Non Operating Interest Income Expense
0.82
+771.31%
-0.12
-133.52%
0.36
+32.36%
0.28
Net Interest Income
0.82
+771.31%
-0.12
-133.52%
0.36
+32.36%
0.28
Interest Income Non Operating
0.91
+81.71%
0.50
+34.13%
0.38
+26.26%
0.30
Interest Income
0.91
+81.71%
0.50
+34.13%
0.38
+26.26%
0.30
Other Income Expense
-2.62
-134.38%
-1.12
-617.13%
0.22
+144.08%
-0.49
Gain On Sale Of Security
-0.16
-660.71%
0.03
-87.04%
0.22
+144.08%
-0.49
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Net Income From Continuing Operation Net Minority Interest
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Net Income From Continuing And Discontinued Operation
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Net Income Continuous Operations
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Normalized Income
-7.69
-20.17%
-6.40
+10.21%
-7.13
+58.98%
-17.38
Net Income Common Stockholders
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Diluted EPS
-2.39
+70.42%
-8.08
+73.07%
-30.00
+76.53%
-127.80
Basic EPS
-2.39
+70.42%
-8.08
+73.07%
-30.00
+76.53%
-127.80
Basic Average Shares
4.31
+363.17%
0.93
+303.31%
0.23
+65.23%
0.14
Diluted Average Shares
4.31
+363.17%
0.93
+303.31%
0.23
+65.23%
0.14
Diluted NI Availto Com Stockholders
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Insurance And Claims
0.38
-2.83%
0.39
-42.54%
0.68
-38.12%
1.09
Rent And Landing Fees
0.03
-70.94%
0.12
-55.17%
0.26
-34.91%
0.40
Rent Expense Supplemental
0.03
-70.94%
0.12
-55.17%
0.26
-34.91%
0.40
Total Other Finance Cost
0.10
-84.80%
0.62
+5581.82%
0.01
-50.00%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
18.63
+0.69%
18.50
+11.25%
16.63
+0.41%
16.56
Current Assets
18.63
+15.52%
16.12
+21.79%
13.24
-10.09%
14.72
Cash Cash Equivalents And Short Term Investments
18.16
+18.43%
15.33
+21.27%
12.64
-8.29%
13.79
Cash And Cash Equivalents
3.98
-14.34%
4.65
+62.60%
2.86
+41.91%
2.02
Other Short Term Investments
14.17
+32.70%
10.68
+9.18%
9.78
-16.89%
11.77
Receivables
0.08
-61.72%
0.21
+26.67%
0.17
+5.10%
0.16
Other Receivables
0.08
-61.72%
0.21
+26.67%
0.17
+5.10%
0.16
Prepaid Assets
0.27
-42.33%
0.46
+46.98%
0.32
-52.84%
0.67
Restricted Cash
0.12
+2.48%
0.12
+3.42%
0.12
+2.63%
0.11
Total Non Current Assets
0.00
-100.00%
2.38
-29.91%
3.39
+84.54%
1.84
Net PPE
—
0.00
-100.00%
0.12
-62.91%
0.34
Gross PPE
—
1.10
-3.58%
1.14
-13.66%
1.32
Accumulated Depreciation
—
-1.10
-8.24%
-1.02
-3.14%
-0.99
Properties
—
0.00
0.00
0.00
Machinery Furniture Equipment
—
0.13
+0.00%
0.13
+0.00%
0.13
Other Properties
—
0.74
-5.39%
0.78
-18.85%
0.96
Leases
—
0.24
+0.43%
0.23
+0.00%
0.23
Investments And Advances
0.00
-100.00%
2.12
-35.10%
3.27
+117.67%
1.50
Long Term Equity Investment
0.00
-100.00%
2.12
-35.10%
3.27
0.00
Total Liabilities Net Minority Interest
2.85
+30.92%
2.17
-20.98%
2.75
-12.36%
3.14
Current Liabilities
2.85
+30.92%
2.17
-20.98%
2.75
-11.12%
3.09
Payables And Accrued Expenses
2.29
+45.73%
1.57
-26.57%
2.14
-22.62%
2.76
Payables
2.00
+52.59%
1.31
-30.07%
1.88
-26.80%
2.57
Accounts Payable
2.00
+53.13%
1.31
-30.39%
1.88
-26.60%
2.56
Other Payable
0.00
-66.67%
0.01
—
0.01
Current Accrued Expenses
0.28
+10.55%
0.26
-1.16%
0.26
+32.14%
0.20
Pensionand Other Post Retirement Benefit Plans Current
0.56
-7.63%
0.60
+5.60%
0.57
+256.88%
0.16
Current Debt And Capital Lease Obligation
—
—
0.04
-76.02%
0.17
Current Capital Lease Obligation
—
0.00
-100.00%
0.04
-76.02%
0.17
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
0.04
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.04
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.04
Stockholders Equity
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Common Stock Equity
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Capital Stock
3.41
+359.30%
0.74
+255.02%
0.21
+198.57%
0.07
Common Stock
3.41
+359.30%
0.74
+255.02%
0.21
+198.57%
0.07
Share Issued
6.58
+295.31%
1.66
+295.98%
0.42
+200.28%
0.14
Ordinary Shares Number
6.58
+295.31%
1.66
+295.98%
0.42
+200.28%
0.14
Additional Paid In Capital
223.46
+3.23%
216.47
+4.54%
207.08
+3.47%
200.14
Retained Earnings
-210.78
-5.14%
-200.47
-3.90%
-192.95
-3.72%
-186.04
Gains Losses Not Affecting Retained Earnings
-0.30
+27.16%
-0.42
+8.37%
-0.45
+39.06%
-0.74
Other Equity Adjustments
-0.30
+27.16%
-0.42
+8.37%
-0.45
+39.06%
-0.74
Total Equity Gross Minority Interest
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Total Capitalization
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Working Capital
15.78
+13.12%
13.95
+33.01%
10.49
-9.81%
11.63
Invested Capital
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Total Debt
—
0.00
-100.00%
0.04
-80.93%
0.21
Capital Lease Obligations
—
0.00
-100.00%
0.04
-80.93%
0.21
Net Tangible Assets
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Tangible Book Value
15.78
-3.34%
16.33
+17.64%
13.88
+3.40%
13.42
Available For Sale Securities
—
—
—
1.50
Investmentin Financial Assets
—
—
0.00
-100.00%
1.50
Investmentsin Associatesat Cost
0.00
-100.00%
2.12
-35.10%
3.27
0.00
Non Current Note Receivables
0.00
-100.00%
0.26
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.32
-7.40%
-5.88
+4.19%
-6.14
+66.83%
-18.50
Cash Flow From Continuing Operating Activities
-6.32
-7.40%
-5.88
+4.19%
-6.14
+66.83%
-18.50
Net Income From Continuing Operations
-10.31
-37.14%
-7.52
-8.75%
-6.91
+61.31%
-17.87
Depreciation Amortization Depletion
0.00
-100.00%
0.08
+167.74%
0.03
-11.43%
0.04
Depreciation
0.00
-100.00%
0.08
+167.74%
0.03
-11.43%
0.04
Depreciation And Amortization
0.00
-100.00%
0.08
+167.74%
0.03
-11.43%
0.04
Other Non Cash Items
-0.02
-103.44%
0.61
+1400.00%
-0.05
-30.56%
-0.04
Stock Based Compensation
0.55
+2.82%
0.53
-40.47%
0.89
-31.17%
1.30
Asset Impairment Charge
2.46
+114.93%
1.15
0.00
0.00
Operating Gains Losses
0.08
+575.00%
0.01
-7.69%
0.01
-97.51%
0.52
Gain Loss On Investment Securities
0.08
+575.00%
0.01
-7.69%
0.01
-97.51%
0.52
Unrealized Gain Loss On Investment Securities
0.00
0.00
+100.00%
-0.27
0.00
Change In Working Capital
0.91
+225.27%
-0.73
-651.52%
0.13
+105.39%
-2.45
Change In Receivables
0.24
+225.00%
-0.19
-155.65%
0.34
+15.00%
0.30
Change In Payables And Accrued Expense
0.67
+225.37%
-0.54
-151.64%
-0.21
+92.26%
-2.75
Change In Payable
0.67
+225.37%
-0.54
-151.64%
-0.21
+92.26%
-2.75
Change In Account Payable
0.69
+221.72%
-0.57
+16.15%
-0.68
+70.53%
-2.31
Change In Other Working Capital
—
0.01
+113.21%
-0.05
—
Investing Cash Flow
-3.38
-203.78%
-1.11
-238.88%
0.80
-95.44%
17.56
Cash Flow From Continuing Investing Activities
-3.38
-203.78%
-1.11
-238.88%
0.80
-95.44%
17.56
Net PPE Purchase And Sale
—
0.00
0.00
+100.00%
-0.00
Purchase Of PPE
—
0.00
0.00
+100.00%
-0.00
Capital Expenditure
—
—
—
-0.00
Net Investment Purchase And Sale
-3.38
-291.99%
-0.86
-137.43%
2.30
-86.91%
17.57
Purchase Of Investment
-4.99
+21.67%
-6.37
-0.51%
-6.33
-63.52%
-3.87
Sale Of Investment
1.61
-70.73%
5.50
-36.24%
8.63
-59.73%
21.44
Net Business Purchase And Sale
0.00
0.00
+100.00%
-1.50
0.00
Purchase Of Business
0.00
0.00
+100.00%
-1.50
0.00
Net Other Investing Changes
—
-0.25
—
—
Financing Cash Flow
9.03
+2.73%
8.79
+42.05%
6.18
+8735.71%
0.07
Cash Flow From Continuing Financing Activities
9.03
+2.73%
8.79
+42.05%
6.18
+8735.71%
0.07
Net Common Stock Issuance
9.03
+2.73%
8.79
+42.05%
6.18
+8735.71%
0.07
Proceeds From Stock Option Exercised
—
—
0.00
0.00
Changes In Cash
-0.66
-136.99%
1.79
+111.67%
0.85
+197.70%
-0.87
Beginning Cash Position
4.77
+60.28%
2.98
+39.81%
2.13
-28.95%
3.00
End Cash Position
4.11
-13.91%
4.77
+60.28%
2.98
+39.81%
2.13
Free Cash Flow
-6.32
-7.40%
-5.88
+4.19%
-6.14
+66.84%
-18.50
Amortization Of Securities
0.01
+188.24%
-0.02
-189.47%
0.02
+1050.00%
-0.00
Common Stock Issuance
9.03
+2.73%
8.79
+42.05%
6.18
+8735.71%
0.07
Earnings Losses From Equity Investments
—
-0.01
0.00
0.00
Issuance Of Capital Stock
9.03
+2.73%
8.79
+42.05%
6.18
+8735.71%
0.07
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category